NZ760921A - Plasminogen treatment of conditions associated with pai-1 overexpression - Google Patents

Plasminogen treatment of conditions associated with pai-1 overexpression

Info

Publication number
NZ760921A
NZ760921A NZ760921A NZ76092118A NZ760921A NZ 760921 A NZ760921 A NZ 760921A NZ 760921 A NZ760921 A NZ 760921A NZ 76092118 A NZ76092118 A NZ 76092118A NZ 760921 A NZ760921 A NZ 760921A
Authority
NZ
New Zealand
Prior art keywords
plasminogen
disease
pai
level
treatment
Prior art date
Application number
NZ760921A
Other languages
English (en)
Inventor
Lyne Gagnon
Pierre Laurin
Brigitte Grouix
Original Assignee
Prometic Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Inc filed Critical Prometic Biotherapeutics Inc
Publication of NZ760921A publication Critical patent/NZ760921A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ760921A 2017-06-23 2018-06-22 Plasminogen treatment of conditions associated with pai-1 overexpression NZ760921A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523901P 2017-06-23 2017-06-23
PCT/IB2018/000655 WO2018234861A1 (en) 2017-06-23 2018-06-22 Plasminogen treatment of conditions associated with pai-1 overexpression

Publications (1)

Publication Number Publication Date
NZ760921A true NZ760921A (en) 2026-01-30

Family

ID=64737041

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ760921A NZ760921A (en) 2017-06-23 2018-06-22 Plasminogen treatment of conditions associated with pai-1 overexpression

Country Status (21)

Country Link
US (1) US11826404B2 (https=)
EP (1) EP3641888B1 (https=)
JP (1) JP2020524689A (https=)
KR (1) KR20200019217A (https=)
CN (1) CN110831668B (https=)
AU (1) AU2018287316B2 (https=)
BR (1) BR112019027229A2 (https=)
CA (1) CA3068153A1 (https=)
CL (1) CL2019003789A1 (https=)
DK (1) DK3641888T3 (https=)
ES (1) ES2965937T3 (https=)
FI (1) FI3641888T3 (https=)
IL (1) IL271470B2 (https=)
MX (1) MX2019015741A (https=)
MY (1) MY203136A (https=)
NZ (1) NZ760921A (https=)
RU (1) RU2020100080A (https=)
SG (1) SG11201912813SA (https=)
TW (1) TWI868051B (https=)
WO (1) WO2018234861A1 (https=)
ZA (1) ZA202000280B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
WO2018107688A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗脂肪肝的方法
WO2018107707A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
TWI787732B (zh) * 2020-02-06 2022-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療多發性硬化症的方法和藥物
TW202342093A (zh) * 2020-03-24 2023-11-01 大陸商深圳瑞健生命科學研究院有限公司 一種治療阿茲海默症的方法和藥物
KR20220156934A (ko) * 2020-03-24 2022-11-28 탈렌젠 인터내셔널 리미티드 잘못 접힌 단백질 및 이의 응집체 분해의 촉진 방법 및 약물
WO2021190561A1 (zh) * 2020-03-24 2021-09-30 泰伦基国际有限公司 一种治疗帕金森病的方法和药物
CN112174979B (zh) * 2020-10-27 2021-09-07 黑龙江中医药大学 一种治疗多囊卵巢综合征的药物及其制备方法
WO2026006092A1 (en) * 2024-06-24 2026-01-02 The Cleveland Clinic Foundation Enzyme encapsulated nanoparticles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
AU3173301A (en) * 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
AU2007290881B2 (en) * 2006-08-28 2013-03-07 Omnio Healer Ab Candidates against infection
US20100028321A1 (en) 2006-08-28 2010-02-04 Omnio Healer Ab Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
TN2016000048A1 (en) * 2013-08-13 2017-07-05 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
US11207387B2 (en) * 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11154595B2 (en) * 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis
EP3556386A4 (en) 2016-12-15 2020-07-08 Talengen International Limited METHOD FOR PREVENTING AND TREATING MEDICINALLY INDUCED KIDNEY INJURY

Also Published As

Publication number Publication date
JP2020524689A (ja) 2020-08-20
CN110831668A (zh) 2020-02-21
US11826404B2 (en) 2023-11-28
EP3641888B1 (en) 2023-10-11
BR112019027229A2 (pt) 2020-07-07
IL271470B2 (en) 2025-07-01
RU2020100080A (ru) 2021-07-23
IL271470A (en) 2020-01-30
CL2019003789A1 (es) 2020-07-10
DK3641888T3 (da) 2024-01-02
ZA202000280B (en) 2021-08-25
CA3068153A1 (en) 2018-12-27
AU2018287316A1 (en) 2020-02-06
RU2020100080A3 (https=) 2021-11-02
AU2018287316B2 (en) 2024-09-19
MY203136A (en) 2024-06-10
TWI868051B (zh) 2025-01-01
MX2019015741A (es) 2020-11-11
TW201904990A (zh) 2019-02-01
EP3641888A4 (en) 2021-03-10
ES2965937T3 (es) 2024-04-17
KR20200019217A (ko) 2020-02-21
FI3641888T3 (fi) 2023-12-19
WO2018234861A1 (en) 2018-12-27
CN110831668B (zh) 2024-04-12
US20210330761A1 (en) 2021-10-28
EP3641888A1 (en) 2020-04-29
IL271470B1 (en) 2025-03-01
SG11201912813SA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
NZ760921A (en) Plasminogen treatment of conditions associated with pai-1 overexpression
GB201907283D0 (en) Use of cannabidiol in the treatment of epileptic spams
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
PH12019501120A1 (en) Methods of treating inflammatory conditions
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
MY199581A (en) Plasminogen replacement therapy for plasminogen-deficiency
MX371153B (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
MY192055A (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
MX2017003624A (es) Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas.
MX2022010638A (es) Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
EP3598980A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
MA50441A (fr) Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild)
MX2017005284A (es) Nuevos derivados de pirazolopirimidina de la cinasa inductora de nf-kb (nk).
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
EP3443966A4 (en) COMPOSITION FOR THE TREATMENT OF CHRONIC LUNG DISEASE WITH EXOSOM FROM THROMBINE-TREATED STEM CELLS
EP4285993A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2017014782A (es) Metodo para el tratamiento de enfermedad neurologica.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
ZA202002103B (en) Compounds as mpges-1 inhibitors
MX343366B (es) Peptidos de nd2 y metodos de tratamiento de enfermedad neurologica.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
WO2015036643A3 (es) Marcador para predecir metástasis del cáncer de mama
EA201991294A1 (ru) Замещенное производное бензимидазола в качестве модулятора активности tnf